Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
Browsing: drug development
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
ESMO WCGI: Trifluridine and tipiracil show promise as metastatic gastric cancer treatment in Phase III trial
Clinical data demonstrates improvement in metastatic gastric cancer patient overall survival in comparison with the placebo.
A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).
A study led by researchers at The Institute of Cancer Research (London, UK) has uncovered numerous ways of targeting prostate cancer.
To mark World Health Day we spoke with Ivo Abraham from the University of Arizona (AZ, USA) about the role that biosimilars play in expanding access to cancer treatments, particularly in regards to the biosimilar filgrastim-sndz.
In this interview find out what advancements have been made in the field of biosimilars and how they are helping improve access to cancer medicines.
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.